What to Expect From ViroPharma
ViroPharma (NAS: VPHM) is expected to report Q2 earnings on Thursday. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict ViroPharma's revenues will wither -18.4% and EPS will wane 47.2%.
The average estimate for revenue is $105.1 million. On the bottom line, the average EPS estimate is $0.19.
Last quarter, ViroPharma reported revenue of $135.8 million. GAAP reported sales were 6.9% higher than the prior-year quarter's $127.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.25. GAAP EPS of $0.26 for Q1 were 35% lower than the prior-year quarter's $0.40 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 76.4%, 870 basis points worse than the prior-year quarter. Operating margin was 30.5%, 1,710 basis points worse than the prior-year quarter. Net margin was 14.7%, 1,400 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $448.9 million. The average EPS estimate is $0.92.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 1,205 members rating the stock outperform and 39 members rating it underperform. Among 295 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 286 give ViroPharma a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on ViroPharma is hold, with an average price target of $33.07.
- Add ViroPharma to My Watchlist.
The article What to Expect From ViroPharma originally appeared on Fool.com.Seth Jaysonhad no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.